

Gout insights Impact on Māori

Establishing the baseline: November 2021

Version 1.1

Authors: Jason Arnold, Robyn Harris, Katherine Graham

ISBN: 978-0-9951144-2-5

Acknowledgements:

The authors would like to thank the following people for their guidance and review of the insights provided here:

- *Pharmac*, particularly Dr Scott Springford Metcalfe, Sandhaya (Sandy) Bhawan, Sarah Beri, Angela Cathro, Liz Barlow
- *Ministry of Health*: Carmela Petagna, Kirk Paterson, James Greenwell, Hilary Sharpe, and Sara Chester
- *Health Quality Safety Commission*: Alexis Wevers
- *Clinical Specialist*, Gout: Professor Nicola Dalbeth
- *University of Otago*, Associate Professor Lianne Parkin, and Dr Simon Horsburgh
- *Flax Analytics*, Dr Liz Ellison-Loschmann, Dr Mona Jeffreys, Dr Fiona McKenzie
- *General Practitioner*, Dr Sean Hanna

Disclaimer

All care has been taken in developing the methodology and insights contained in this report. However, Pharmac gives no indemnity as to the correctness of the information or the data given here. Pharmac shall not be liable for any loss or damage arising directly or indirectly from use of the data or insights supplied in this report.

Introduction

Tēnā koutou katoa

We are excited to introduce a series of research insights being developed by Pharmac to implement our Medicine Access Equity Monitoring and Outcomes Framework. Our first report focuses on the prescribing and dispensing of medicines for gout.

Future reports will focus on conditions and populations that are priorities for health equity. Gout insights for Pacific peoples will be released shortly, and measures for cardiovascular disease, diabetes, asthma, and chronic obstructive pulmonary disease are being developed.

Our commitment to Te Tiriti o Waitangi

Sharing these insights supports Te Rautaki o Te Whaioranga, Pharmac's Māori Responsiveness Strategy, and our commitment to Te Tiriti o Waitangi. Our goal is to advance Māori health and aspirations – to achieve pae ora for Māori – through tino rangatiratanga, partnership, active protection, options, and equity.

We will therefore routinely and transparently report on Māori access to medicines and our role in working to address equity gaps, and we will work with our partners across the health and disability sector to influence prescribing and dispensing behaviour in primary care.

Turning these insights into action

Te Pataka Whaioranga has a strategic priority to enable equitable access and use of medicines by influencing medicines availability, accessibility, affordability, acceptability and appropriateness. Research like this supports this priority, but it is not enough on its own.

We are using the data and insights and working with our partners across the health and disability sector to influence prescribing and dispensing behaviour. We're also examining our own processes for improving access to funded medicines. This work has started for Gout and will expand to other conditions in this research series.

What you can do

These insights will be particularly useful for the health system, including health practitioners, health workers, and policy makers.

Our key findings outline where inequities lie in access to preventive gout medicines – and we will be monitoring these over time. The insights are concerning but not surprising. There are systemic and societal influences that we need to address to achieve equitable outcomes. While research like this supports our goal for Māori to achieve their best health and wellbeing, we know it is not enough on its own.

We ask that you reflect on these insights in your work and do what you can.

As part of the New Zealand health and disability sector, we all have a role to play in addressing current health inequities. We hope these reports, and the practical resources available on He Ako Hiringa demonstrate what can be done in terms of equitable access to medicines.

Ensuring rigour in our research

An established external review process is in place to ensure the data used within each report is robust and has credibility with experts in the field before its released. External review of these insights included Pharmacoepidemiology, Clinical specialist (condition specific), General practitioner, and Māori Health (including epidemiology, framing of our narrative, and Māori clinicians).

We welcome your feedback

These insights are intended to prompt discussion, we welcome and encourage your thoughts and ideas.

Please get in touch with us at accessequity@pharmac.govt.nz

He tono – a request

Tera te haeata takiri ana mai i runga o Hikurangi
Ara whaiuru, whaiuru, whaiuru
Ara whaiato, whaiato, whaiato
I ara rā tini! I ara rā tini! Arara rī
Te Pātaka Whaioranga!
Kia mau. Kia mataara.

There yonder breaks the dawn on the peak of Hikurangi
Now seek entry, seek access, seek passage
Now seek collaboration, seek combination, seek togetherness
There, a culmination for the multitude
The Storehouse of Wellbeing!
Be alert. Be vigilant.

Ngā mihi



Trevor Simpson
Chief Māori Advisor



Dr David Hughes
Chief Medical Officer

Key findings

An estimated 10,400 more Māori need preventive gout medicine each year

Our primary finding is that, to help achieve equity in access to medicines, we need more Māori started on preventive gout medicine at a younger age. We have estimated that 10,400 more Māori need to be dispensed preventive gout medicine each year to achieve equity of access to medicines.

We know that there are many hurdles in the health system that make it harder for Māori to access medicines for gout. We also know that biological factors, such as kidney disease and genetic variants, and some medicines contribute to higher prevalence of gout in Māori.

Our insights support the following recommendations for practitioners

- If young Māori present with joint pain, gout should be considered as a cause.
- Practitioners should be aware of the harms of long-term use of NSAIDs for Māori with gout and consider other treatments as appropriate.
- Practitioners are encouraged to follow up with and repeat prescribe preventive gout medicine for young Māori in particular.
- People working with whānau can raise awareness of genetic predisposition to gout in Māori. This can reduce whakamā associated with gout and encourage preventive gout treatment.

Findings demonstrate inequities between Māori and non-Māori, non-Pacific

1. While Māori are approximately twice as likely to be dispensed medicine for gout compared to non-Māori, non-Pacific peoples, this is still not enough to meet health need for Māori.
2. Māori start being dispensed preventive gout medicine 10 years earlier than non-Māori, non-Pacific peoples. Given the much higher gout disease burden, Māori may need to start even earlier.
3. The prescribing and dispensing of non-steroidal anti-inflammatory drugs (NSAIDs) for people receiving preventive gout medicines is high, especially for Māori.
4. For both Māori and non-Māori, non-Pacific peoples, approximately two-thirds of people previously dispensed a preventive medicine for gout are not continuing to receive it regularly.
5. For both Māori and non-Māori, non-Pacific peoples, the younger the person, the less likely they are to be regularly dispensed preventive gout medicine. Only 14% of Māori aged 25-44 have regular dispensing after being initially dispensed these medicines.
6. Māori have higher rates of being dispensed at least one prescription for a preventive gout medicine a year. However, they have lower rates of medicine possession (having enough medicine to cover that year) compared to non-Māori, non-Pacific peoples.
7. Māori are 6.9 times more likely to be hospitalised with a primary diagnosis of gout compared with non-Māori, non-Pacific peoples.
8. Māori are more likely to live with both gout and other long-term conditions, such as type 2 diabetes, than non Māori, non-Pacific peoples.
9. In 2018/2019, 60% of Māori hospitalised for gout were not receiving preventive gout medicine in the six months prior to hospitalisation.
10. It is likely the excess hospitalisations are partly because practitioners are not prescribing preventive gout medicines to enough Māori.

Background

What is gout

Gout is a form of arthritis and a life-long condition. Gout significantly affects people's social connections, opportunities for employment and general wellbeing. The symptoms and risk of complications are preventable if people with gout take medicine daily to reduce blood urate levels.

Gout occurs when high levels of urate in the blood cause urate crystals to form in the joints. This can cause severe pain and damage to the joints. Gout is associated with a higher risk of other conditions such as heart disease and kidney disease. People with gout experience reduced quality of life and life expectancy (3, 4).

Prevalence of gout in New Zealand

Gout is estimated to affect around 6% of adult New Zealanders aged 20 years and over (5). Males have approximately three times the prevalence of gout compared with females.

Māori are approximately two times more likely to live with gout compared to non-Māori, non-Pacific peoples and three times more likely to live with gout for those aged between 20-44 years (5). Māori have a younger population so are disproportionately affected by gout. Approximately 70% of Māori are under 40 years of age compared to 54% of the entire New Zealand population (6).

Biological factors – such as kidney disease, genetic variants, and some medicines – contribute to higher prevalence of gout in Māori compared to non-Māori, non-Pacific peoples. Māori are also more likely to be affected by severe gout, early onset gout, tophaceous disease, and accelerated joint damage (7).

Populations compared in this report

This paper compares Māori health data with the data of those who do not identify themselves as either Māori or Pacific peoples. Throughout the paper this comparator group is referred to as “non-Māori, non-Pacific peoples”. In all figures Pacific peoples are not included. Please refer to “Pacific people's health - Gout data insights” for information relevant to this population group. The titles and sources of all the figures are provided at the end of this insights report.

Medicines in this report

The gout medicines considered in this insight have been listed in Appendix A. Note that for the population with prevalent gout (1), we have included either gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine, but for any dispensing, possession and regular dispensing we have confined these to gout-specific urate lowering preventive therapy (allopurinol, febuxostat, benzbromarone, probenecid) alone, as these are the medicines people should be prescribed long-term (whereas colchicine is used to treat acute attacks of gout). Preventive therapy relates to the prevention of gout flares, rather than the prevention of the gout condition

The data insights

1. Māori are more likely to be dispensed a gout-specific medicine compared to non-Māori, non-Pacific peoples but still not enough according to need

Dispensing data identifies that overall, 11% of Māori (20 years and over) and 6% of non-Māori, non-Pacific peoples have ever been treated with a gout specific medicine¹.

However, Māori are still not being dispensed enough gout-specific medicine according to need, as indicated by hospitalisation rates for gout (see figure 10).

Furthermore, dispensing data represents only the medicated population group. Prevalence of gout is likely to be higher than what is indicated by dispensing data alone particularly for Māori where there are known inequities in access to the prescribing and dispensing of preventive medicines for long-term conditions (8). In addition, there will be people who have been prescribed but not dispensed a preventive gout medicine.

Many barriers contribute to inequities in medicine access. These include structural barriers created through the colonial history of Aotearoa New Zealand, prescribing bias, cost and access to medicines and health care, background social determinants of health and racism.

2. Māori start preventive gout treatment earlier than non-Māori, non-Pacific peoples

Percentage of NZ population ever on gout specific medicine up to 2018/19 by gender




Figure 1

Percentage of people first dispensed preventive gout medicine 2014/15-2018/19 by age and ethnicity




Figure 2

The black lines with arrows indicate the mean age that people, aged 15+ years, were started on preventive gout medicine for the first time, for Māori and non-Māori, non-Pacific peoples respectively. They show that, between 1 July 2014 and 30 June 2019, Māori were started on

¹ Ever been dispensed gout specific medicines include gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine since 2006.

preventive gout medicine, on average, 10 years earlier than non-Māori, non-Pacific peoples. This indicates there is higher need in Māori earlier in life.

Given the much higher gout disease burden in Māori, it is possible that Māori should be started on their preventive gout medicine even earlier relative to non-Māori, non-Pacific peoples.

3. The prescribing of NSAIDs in people with gout is high, especially for Māori

Non-steroidal anti-inflammatory drugs (NSAIDs) are used to manage the pain of gout when it flares up. They do not stop urate crystal deposition or joint damage. People should be moved away from NSAIDs to long-term preventive medicines, early.

Long term use of NSAIDs for gout causes harm, kidney damage, and cardiovascular disease.

Although the equity gap is starting to decline, prescribing rates remain unacceptably high for Māori.

This requires awareness and behavioural change from prescribers and support for people taking these medicines to understand the impacts of long-term use.

Note, this data covers people dispensed preventive gout medicine, and who have been dispensed a NSAID for any condition. It does not include NSAIDs bought over the counter, nor does it look at alternative colchicine or oral corticosteroid use for severe gout attacks.

Percentage of population 20+ dispensed any preventive gout medicine and a NSAID 2014-2020 by ethnicity




Figure 3

Definitions: Any dispensing, possession, and regular dispensing

Dispensing data can be used to determine whether a person has had access to medicines to allow them to take those medicines on a regular basis.

Dispensing of medicines can be measured in two ways:²

- (1) **Any dispensing** (persistence): The percentage of people who once starting a preventive medicine continue to be dispensed at least one prescription for the condition in the year.
- (2) **Possession**: The percentage of people with 'any dispensing' who have had enough medicine prescribed and dispensed to cover that year.

Regular dispensing (persistence and possession combined): The percentage of people who once being started on a preventive medicine have had any dispensing in the year (persistence) and have had enough medicine dispensed to cover that year (possession). This represents the percentage of people who have ever³ been started on a preventive gout medicine who continue to be adequately treated.

Note: This data has not included dose appropriateness.

² These two ways can also be defined using the pharmaco-epidemiological terms persistence and possession

³ Since 2006

4. For both Māori and non-Māori, non-Pacific peoples, approximately two-thirds of people previously dispensed a preventive medicine for gout⁴ are not continuing to receive it regularly.

Gout is a controllable disease. Initial flares usually involve a single joint and can be treated in the community and followed up by starting preventive medicine.

Continuation and regular use of preventive medicines for gout are low for both Māori and non-Māori, non-Pacific peoples.




Figure 4 ethnicity

5. For both Māori and non-Māori, non-Pacific peoples, the younger the person, the less likely they are to be regularly dispensed preventive gout medicine




Figure 5

NB: The numbers indicate the number of people with gout.

⁴ Preventive medicines for gout are gout-specific urate lowering therapy, allopurinol, febuxostat, benzbromarone, probenecid Note those taking these medicines as part of cancer therapy have not been excluded in these insights but will be in future iterations.

Younger people are less likely to be regularly dispensed preventive gout medicine, irrespective of ethnicity, compared with older people. A greater proportion of Māori are in the younger age groups, which impacts the overall rate of regular dispensing for Māori (see Figure 4).

Māori start preventive gout treatment earlier, therefore at any age are likely to have had gout for a longer period of time – this may have relevance for disease severity.

6. Māori have less medicine possession of preventive gout medicine than non-Māori, non-Pacific peoples

When ‘regular dispensing’ is broken down to ‘any dispensing’ and ‘possession’ we see that Māori have greater rates of ‘any dispensing’ (receiving at least one prescription a year after initially being prescribed the medicine) but lower rates of ‘possession’ (receiving enough medicine to cover a given year) compared to non-Māori, non-Pacific peoples.




Figure 6




Figure 7

These differences in ‘any dispensing’, ‘possession’ and ‘regular dispensing’ between ethnicities do not take into account:

- the very high relative gout disease burden encountered by Māori
- disease severity
- the need for more Māori to be prescribed preventive medicines earlier.

In the year ending June 2019, 25,450 (6.0%) Māori aged 20+ were on preventive gout medicine. Another 22,260 (5.3%) Māori had started preventive gout medicine previously but were no longer receiving any dispensing of them in the year.

Similarly in 2019, 85,800 (3.1%) non-Māori, non-Pacific peoples aged 20+ were on preventive gout medicine. Another 90,650 (3.3%) were no longer receiving any dispensing of them in the year.

7. Māori are more likely to live with both gout and other long-term conditions, such as type 2 diabetes, than non-Māori, non-Pacific peoples.

Multi-morbidity disproportionately impacts Māori. There is a high co-prevalence of gout and diabetes in the adult population of Aotearoa New Zealand.

One in three Māori with gout have been identified as having diabetes as opposed to one in five of European ethnicity (2).

This is important as living with another long-term condition such as diabetes as well as gout adds to the overall disease burden experienced by Māori. The presence of gout may also be a marker of health risk which has important implications for clinical practice (2).

2018/19 dispensing data indicates that 15% of non-Māori, non-Pacific peoples and 23% of Māori have been dispensed preventive gout medicine and medicine to treat type 2 diabetes.

Higher rates of co-morbidity for Māori also occur for cardiovascular and renal disease.

Percentage of people dispensed any preventive gout medicine and also any medicine to treat type 2 diabetes in 2018/19 by ethnicity




Figure 8

8. Māori are 6.9 times more likely to be hospitalised with a primary diagnosis of gout compared with non-Māori, non-Pacific peoples

Differences in hospitalisation rates, between Māori and non-Māori, non-Pacific peoples are evident across all age groups and in terms of the **absolute gap** is largest in the 65+ age group. However, the equity gap (relative gap) is largest in the 25-44 year age group.

If Māori people were hospitalised for gout at the same rate as non-Māori, non-Pacific Peoples, there would have been 390 fewer hospitalisations in 2019.

In 2019, 1,430 people were hospitalised for gout:

- 470 were Māori (age standardised rate (ASR) 1.05 per 1000⁵)
- 580 were non-Māori/non-Pacific peoples (ASR 0.15 per 1000)⁶.

Rate of hospitalisations with a primary diagnosis of gout 2014/15-2018/19 by age and ethnicity




Figure 9

Hospitalisations are likely to represent only a small part of the persisting burden of gout Māori experience in the community.

⁵ Age Standardised to the 2013 Māori population

⁶ See Pacific Health gout data insights for data relevant for Pacific peoples.

9. In 2018/2019, 60% of Māori hospitalised for gout were not receiving preventive gout medicine in the six months prior to hospitalisation.

Hospitalisations might be avoided if access to early preventive gout medicine is improved.




Figure 10

One quarter of Māori hospitalised for gout did not receive a preventive gout medicine before or after hospitalisation. A further 5% had a prescription for a preventive gout medicine in the six months before hospitalisation but not afterwards⁷.

The fact that Māori are still not on preventive medicine in the six months after hospitalisation for gout shows there is unmet need, and that the health system needs to do more.

Interventions and solutions need to better support Māori with gout across their life journey.

10. Practitioners are encouraged to start prescribing more Māori preventive gout medicines earlier.

There are significant equity gaps in hospitalisations that cannot be sufficiently explained by the rates of regular dispensing and possession of preventive gout medicines between population groups. It is likely the excess hospitalisations are partly because practitioners are not prescribing preventive gout medicines to enough Māori, particularly in the younger age groups. Barriers to medicines being dispensed to Māori also need to be removed.

To achieve equity an estimated 10,400 more Māori need to be started on preventive gout medicine each year.

⁷ May include some people who have subsequently passed away.

Number of Māori dispensed any preventive gout medicine and those needing to start to achieve equity in 2018/19




Figure 11

List of figures:

Figure 1: Percentage of population that has ever been on gout medication previously and is still alive. *Source:* People identified as ever being on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) on or before Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 2: Age of people starting preventive gout medication. *Source:* People starting preventive gout medication for the first time between 1 July 2014 and 30 June 2019 aged 15+ years as identified from the NZ Pharmaceutical Collection.

Figure 3: Percentage of people with gout that are receiving NSAIDs. *Source:* Currently on NSAIDs that have been identified as taking preventive gout medication, in the past or currently, between 1 July 2013 and 30 June 2020 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 4: Percentage of people currently on preventive gout medication versus those that have ever been on gout specific medication broken down by Māori vs non-Māori, non-Pacific peoples showing regular dispensing. *Source:* People on current preventive gout medicines and people ever on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) in the Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 5: Figure 4, broken down by age. *Source:* People on current preventive gout medicines and people ever on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) in the Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 6: Figure 4 focused on any dispensing *Source:* People on current preventive gout medicines and people ever on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) in the Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 7: Figure 4 focused on possession of preventive gout medicine. *Source:* People on

current preventive gout medicines with enough medicine to cover the full year in the Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 8: Percentage of people with gout that are being treated for type 2 diabetes. *Source:* People identified as ever being on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) and ever being on diabetes medication (for type 2 diabetes) in the Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection.

Figure 9: Māori versus non-Māori, non-Pacific peoples age specific rates of people hospitalised primarily for gout. *Source:* Age specific and age standardised primary hospitalisations for gout aggregated over a five-year period from 1 July 2014 to 30 June 2019 as identified from the National Minimum dataset.

Figure 10: Hospitalisations primarily for gout in the Year Ending 30 June 2019 compared with pharmaceutical dispensings for preventive gout medicine in the six months before an event or the six months after an event. The dispensing data can then be examined to see if a person was dispensed any preventive medicines relevant to the condition in the six months before; six months after; both six months before and six months after; or neither six months before or six months after.

Figure 11: People that have ever been on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) and the extra people that are estimated to need to start treatment based on the need derived from hospitalisations. *Source:* People identified as ever being on specific gout medicines (gout-specific urate lowering therapy (allopurinol, febuxostat, benzbromarone, probenecid) or colchicine) in the Year Ending 30 June 2019 aged 20+ years as identified using the NZ Pharmaceutical Collection. The number of extra new people starting identified through matching the ratio of age specific new starters on preventive gout medication to the ratio of age specific gout hospitalisations has been added. Hospitalisation are identified from the National Minimum dataset.

References

1. Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. *Rheumatology*. 2012;51(5):901-9.
2. Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. *The New Zealand Medical Journal (Online)*. 2013;126(1368).
3. Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. *BMC Nephrology*. 2019;20(1):93.
4. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric Acid and Cardiovascular Disease: An Update. *Eur Cardiol*. 2016;11(1):54-9.
5. Health Quality & Safety Commission. Atlas of Healthcare Variation - Gout 2021 [Available from: <https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/gout/>].
6. Stats NZ Tatauranga Aotearoa. Estimated Māori population in New Zealand 2021 [Māori ethnic population is the population who identify themselves with the Māori ethnicity with or without other ethnicities. Because ethnicity is self-perceived, people can identify with Māori ethnicity even though they are not descended from a Māori ancestor. Conversely, people may choose to not identify with Māori ethnicity even though they are descended from a Māori ancestor. It is a measure of cultural affiliation (in contrast to race, ancestry, nationality, or citizenship)]. Available from: <https://figure.nz/chart/EstqQdUizXkZOMTt>.
7. Dalbeth N, House ME, Horne A, Te Karu L, Petrie KJ, McQueen FM, et al. The experience and impact of gout in Māori and Pacific people: a prospective observational study. *Clinical rheumatology*. 2013;32(2):247-51.
8. Metcalfe S, Beyene K, Ulrich J, Jones R, Proffitt C, Harrison J, et al. Te Wero tonu - the challenge continues: Māori access to medicines 2006/07-2012/13 update. *NZ Med J*. 2018;131(1485):27-47.

Appendix A: Gout medications

Table 1: Gout medications included in baseline analysis

MONITOR GROUP	CHEMICAL NAME	PREVENTIVE / ACUTE
Allopurinol	allopurinol	Preventive
Benzbromarone	benzbromarone	Preventive
Colchicine	colchicine	Acute
Febuxostat	febuxostat	Preventive
Probenecid	probenecid	Preventive
Non-steroidal anti-inflammatory drugs (NSAIDs)	celecoxib	Acute
	diclofenac sodium	Acute
	diflunisal	Acute
	fenbufen	Acute
	fenoprofen calcium	Acute
	flurbiprofen	Acute
	ibuprofen	Acute
	indomethacin	Acute
	ketoprofen	Acute
	mefenamic acid	Acute
	meloxicam	Acute
	naproxen	Acute
	naproxen sodium	Acute
	phenylbutazone	Acute
	piroxicam	Acute
	rofecoxib	Acute
sulindac	Acute	
tenoxicam	Acute	
tiaprofenic acid	Acute	

Appendix B: Gout ICD-10 codes

Table 2 ICD-10 codes for gout baseline analysis

Code	Description
M100	Idiopathic gout, ankle and foot
	Idiopathic gout, forearm
	Idiopathic gout, hand
	Idiopathic gout, lower leg
	Idiopathic gout, multiple sites
	Idiopathic gout, other site
	Idiopathic gout, pelvic region and thigh
	Idiopathic gout, shoulder region
	Idiopathic gout, site unspecified
	Idiopathic gout, upper arm
M109	Gout, unspecified, ankle and foot
	Gout, unspecified, forearm
	Gout, unspecified, hand
	Gout, unspecified, lower leg
	Gout, unspecified, multiple sites
	Gout, unspecified, other site
	Gout, unspecified, pelvic region and thigh
	Gout, unspecified, shoulder region
	Gout, unspecified, site unspecified
	Gout, unspecified, upper arm